1-4 of 4
Denise Wang
Close
Sort by
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3736.
https://doi.org/10.1182/blood-2021-145926
Published: 2021
Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, John M. Pagel, Catherine C. Coombs, Nirav N. Shah, Nicole Lamanna, Tahla Munir, Ewa Lech-Marańda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Yoon Cheah, Jonathon B. Cohen, Lindsey E. Roeker, Manish R. Patel, Bita Fakhri, Minal A. Barve, Constantine S. Tam, David John Lewis, James N. Gerson, Alvaro J. Alencar, Chaitra S. Ujjani, Ian W. Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna M Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald Tsai, Matthew S. Davids, Jennifer R. Brown, Wojciech Jurczak
Journal: Blood
Blood (2021) 138 (Supplement 1): 391.
https://doi.org/10.1182/blood-2021-147599
Published: 2021